Exact Sciences Co. (NASDAQ:EXAS) Stock Position Raised by Walkner Condon Financial Advisors LLC

Walkner Condon Financial Advisors LLC lifted its holdings in Exact Sciences Co. (NASDAQ:EXAS) by 6.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,517 shares of the medical research company’s stock after buying an additional 534 shares during the period. Walkner Condon Financial Advisors LLC’s holdings in Exact Sciences were worth $447,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Huntington National Bank grew its holdings in shares of Exact Sciences by 838.1% during the third quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock valued at $27,000 after buying an additional 352 shares in the last quarter. RPg Family Wealth Advisory LLC purchased a new position in Exact Sciences in the third quarter valued at about $34,000. Capital Performance Advisors LLP purchased a new position in Exact Sciences in the third quarter valued at about $35,000. Vestor Capital LLC purchased a new position in Exact Sciences in the third quarter valued at about $46,000. Finally, V Square Quantitative Management LLC purchased a new position in Exact Sciences in the third quarter valued at about $47,000. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Exact Sciences Trading Down 2.5 %

Exact Sciences stock opened at $49.31 on Friday. The business has a 50 day moving average price of $56.15 and a two-hundred day moving average price of $60.09. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72. The stock has a market cap of $9.13 billion, a price-to-earnings ratio of -42.14 and a beta of 1.24. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $79.62.

Wall Street Analyst Weigh In

EXAS has been the topic of a number of recent research reports. Canaccord Genuity Group lowered their target price on Exact Sciences from $95.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. TD Cowen boosted their target price on Exact Sciences from $82.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Evercore ISI lowered their target price on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Sanford C. Bernstein boosted their target price on Exact Sciences from $75.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Finally, Benchmark reaffirmed a “buy” rating and issued a $65.00 price target on shares of Exact Sciences in a research report on Monday, January 13th. One investment analyst has rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $72.76.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.